No Association Between HLA-B*57:01 and Prevalence and/or Outcome of Progressive Multifocal Leukoencephalopathy in a French Nationwide Human Immunodeficiency Virus Cohort
Restricted accessResearch articleFirst published online April, 2024
No Association Between HLA-B*57:01 and Prevalence and/or Outcome of Progressive Multifocal Leukoencephalopathy in a French Nationwide Human Immunodeficiency Virus Cohort
Among 34,351 patients living with human immunodeficiency virus with available HLA-B*57:01 included in the Dat'AIDS cohort, 194 patients (0.56%) had a history of progressive multifocal leukoencephalopathy (PML) and 1,746 (5.08%) were carriers of HLA-B*57:01. The frequency of HLA-B*57:01 was similar among patients with history of PML compared with patients without a history of PML (6.19% [95% confidence interval, CI 2.8%–9.6%] vs. 5.08% [95% CI 4.8%–5.3%]; p = .48). Among patients with PML, clinical and biological characteristics at PML diagnosis and the PML outcome were not different according to HLA-B*57:01 status.
Get full access to this article
View all access options for this article.
References
1.
Dalla-PozzaP, HentzienM, AllavenaC, et al.Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6 months of combination antiretroviral therapy. AIDS, 2022; 36(4):539–549; doi: 10.1097/QAD.0000000000003145
2.
GheuensS, FellayJ, GoldsteinDB, KoralnikIJ. Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy. J Neurovirol, 2010; 16(1):41–47; doi: 10.3109/13550280903552438
3.
The International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science, 2010; 330(6010):1551–1557; doi: 10.1126/science.1195271
4.
U.K. Collaborative HIV Cohort Study Steering Committee. HLA B*5701 status, disease progression, and response to antiretroviral therapy: AIDS, 2013; 27(16):2587–2592; doi: 10.1097/01.aids.0000432613.95455.71
5.
KimAY, KuntzenT, TimmJ, et al.Spontaneous control of HCV is associated with expression of HLA-B*57 and preservation of targeted epitopes. Gastroenterology, 2011; 140(2):686–696.e1; doi: 10.1053/j.gastro.2010.09.042
6.
HentzienM, CuzinL, RaffiF, et al.Factors associated with psoriasis in a French Nationwide HIV cohort: The independent role of HLA-B*57:01. AIDS, 2020; 34(7):1057–1063; doi: 10.1097/QAD.0000000000002519
7.
PuglieseP, CuzinL, CabiéA, et al.A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med, 2009; 10(8):504–511; doi: 10.1111/j.1468-1293.2009.00719.x
8.
SundqvistE, BuckD, WarnkeC, et al.JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog, 2014; 10(4):e1004084; doi: 10.1371/journal.ppat.1004084
9.
HanaeiS, SahraianMA, MohammadifarM, et al.Prevalence of anti-JC virus antibody seropositivity in patients with multiple sclerosis: A systematic review and meta-analysis. Intervirology, 2019; 62(5–6):169–173; doi: 10.1159/000507367
10.
MelliezH, Mary-KrauseM, BocketL, et al.Risk of progressive multifocal leukoencephalopathy in the combination antiretroviral therapy era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4). Clin Infect Dis, 2018; 67(2):275–282; doi: 10.1093/cid/ciy074
11.
LoginovaM, KutyavinaS, ParamonovI, et al.The novel HLA-B*57:135 allele was identified during high-resolution HLA typing. HLA, 2020; 96(5):642–644; doi: 10.1111/tan.14053
12.
PayneRP, BranchS, KløverprisH, et al.Differential escape patterns within the dominant HLA-B*57:03-restricted HIV gag epitope reflect distinct clade-specific functional constraints. J Virol, 2014; 88(9):4668–4678; doi: 10.1128/JVI.03303-13
13.
SaundersPM, MacLachlanBJ, PymmP, et al.The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Proc Natl Acad Sci U S A, 2020; 117(21):11636–11647; doi: 10.1073/pnas.1920570117
